GET DAILY SIGNALSWhy Is Replimune Group (REPL) Stock Up +8.47% Today?
Key Takeaways
- REPL shares rose 8.47% to $17.42, extending a powerful rally following the company's fiscal second-quarter results and the early commercial launch of its melanoma therapy.
- The primary catalyst was continued investor enthusiasm over TUDRIQEV, Replimune's newly approved oncolytic immunotherapy, which is showing rapid early adoption among oncology centers.
- Secondary drivers included a narrower-than-expected quarterly loss, an analyst price-target increase, and strength across the broader biotechnology complex.
- The move pushed the stock to multi-year highs, decisively above its previous 52-week peak.
- Traders are now watching for the company's first reported product revenue and further updates on the confirmatory IGNYTE-3 trial.
- For deeper analysis, explore Price Targets, Earnings, and Forecast pages for REPL.
- To see which automated strategies are currently leading the market, visit Trending AI Robots.
Opening Summary
Replimune Group, Inc. (REPL), a Woburn, Massachusetts-based oncology company developing oncolytic immunotherapies, saw its shares climb 8.47% on Thursday, finishing the session around $17.42 versus a prior close of $16.06. The advance added to a dramatic multi-day surge driven by the company's fiscal second-quarter 2027 results and mounting evidence that its lead product, TUDRIQEV, is gaining commercial traction just weeks into its U.S. launch.
TUDRIQEV Launch Momentum
The dominant force behind the rally is early execution on the commercial rollout of TUDRIQEV (vusolimogene oderparepvec-wtpg), an oncolytic immunotherapy approved in combination with nivolumab for advanced cutaneous melanoma that has progressed on an anti-PD-1 regimen. Management reported that the therapy was first delivered to patients on October 6, and that within roughly 20 business days more than 15 institutions had already written prescriptions, while about 20 accounts had placed the drug on formulary. The company has engaged more than 70% of its initial 200 target accounts and holds over a year of in-house manufactured inventory, easing supply concerns as adoption ramps.
Fiscal Second-Quarter Earnings Beat
The earnings-driven move reflects a quarterly update that landed ahead of expectations. Replimune reported a net loss of $57.1 million, or $0.54 per share, for the fiscal second quarter ended September 30, 2026 — a marked improvement from the $83.1 million loss a year earlier and narrower than the consensus estimate of roughly $0.78 per share. The company also trimmed both research and development and selling, general and administrative expenses, signaling a tighter cost base as it transitions from a development-stage to a commercial-stage organization.
Analyst Support and Sector Momentum
Positive sell-side commentary reinforced the move. Jefferies raised its price target on the stock, pointing to rapid formulary access and early prescribing activity across regional centers as evidence of robust demand. At the same time, REPL benefited from a constructive backdrop for biotechnology equities, as investor appetite for newly launched, high-unmet-need oncology assets remained strong. The stock's climb into fresh multi-year territory further supported bullish sentiment.
Market Context and Trading Activity
Thursday's move extended a breakout that has carried REPL well above its prior 52-week high, with the shares breaking through prior resistance near the $16 level. The advance followed a session of heavy trading earlier in the week, reflecting elevated participation as momentum-oriented and institutional buyers repositioned around the launch narrative. The move also outpaced the broader market, underscoring the stock-specific nature of the catalyst rather than a broad risk-on drift.
What Comes Next for REPL
Investors will now focus on whether the early launch momentum converts into reported revenue. The company expects to book its first product sales in the fiscal third quarter and is working toward a permanent J-code — a key reimbursement identifier — expected by April 2027. Continued approval of TUDRIQEV remains contingent on the confirmatory IGNYTE-3 Phase 3 trial, which is actively enrolling, while the RP2 REVEAL program in metastatic uveal melanoma represents a longer-term pipeline opportunity. With a cash balance of $307.8 million expected to fund operations for more than 12 months, execution risk centers on sustaining adoption beyond the initial 200 target accounts and navigating the competitive oncology landscape.
Trending AI Robots
Tickeron's Trending AI Robots page curates the platform's strongest-performing AI trading bots under current market conditions. Tickeron offers hundreds of automated trading bots covering thousands of tickers, with strategies that vary by approach, timeframe, performance metrics, and traded symbols. The featured bots are selected for their recent relative strength, giving traders a focused view of which quantitative strategies are adapting best to today's environment. Explore the page to see how AI-driven signals are navigating moves like the one in REPL.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
REPL's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for REPL turned positive on October 26, 2026. Looking at past instances where REPL's MACD turned positive, the stock continued to rise in 47 of 50 cases over the following month. The odds of a continued upward trend are 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on REPL as a result. In 68 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
REPL moved above its 50-day moving average on October 28, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +28.79% 3-day Advance, the price is estimated to grow further. Considering data from situations where REPL advanced for three days, in 184 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 75%.
Bearish Trend Analysis
The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for REPL crossed bearishly below the 50-day moving average on September 28, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where REPL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
REPL broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for REPL entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. REPL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 80 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (14.323) is normal, around the industry mean (3.151). P/E Ratio (-5.098) is within average values for comparable stocks, (-1.051). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (127.720) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.237).
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 89 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. REPL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of oncolytic immunotherapies
Industry Biotechnology
Advertisement